Author: Claire Cassedy

2016: Kite Pharma, KEI Comments on NIH Proposed Exclusive License for Cancer Treatment

Posted on by Claire Cassedy

Today, KEI submitted comments to the Notice published in the Federal Register on October 5, 2016, entitled “Prospective Grant of Exclusive Patent License: Development of Anti-CD70 Chimeric Antigen Receptors for the Treatment of CD70 Expressing Cancers.” KEI’s comments addressed issues with the NIH’s processes for granting exclusive licenses, and transparency in those licenses, resulting data, trials, pricing, and revenue.
Continue Reading →

Commentary on Hillary Clinton’s Plan to Respond to Unjustified Price Hikes for Long-Available Drugs

Posted on by Claire Cassedy

Democratic presidential nominee Hillary Clinton has published a factsheet presenting, “Hillary’s Plan to Respond to Unjustified Price Hikes for Long-Available Drugs.”

Today via Twitter, KEI Director James Love offered a six point commentary on Secretary Clinton’s proposal to address drug price hikes:

Continue Reading →

Two page summary: What does the TPP do as regards prices of drugs and other medical technologies?

Posted on by Claire Cassedy

Attached is a 2 page summary of the main provisions in the Trans-Pacific Partnership Agreement (TPP) that will lead to higher prices for drugs and other medical technologies.

A pdf version of the note is available here: /wp-content/uploads/KEI-TPP-Briefing-2015-2-A2M.pdf

What does the TPP do as regards prices of drugs and other medical technologies?

KEI TPP Briefing note 2015:2
June 10, 2015
Continue Reading →

Sign-on Letter to USTR, be honest about impact of TPP on prices, access to medicines

Posted on by Claire Cassedy

KEI is circulating a sign on letter to be sent to Ambassador Michael Froman of USTR. We learned that in a USTR has been stating that there was no evidence that stronger intellectual property rules created barriers for access to medicine.

This is a shocking statement for USTR to make, and we are seeking confirmation and clarification of USTR’s assertion. The text of our letter follows below.

If you would like to sign on to this letter, please send your name, city and state of residence, and affiliation if any, along with contact details (only for confirmation if necessary), to:

Continue Reading →

KEI Comments to DHHS on WHA68 agenda 11.2, Framework of Engagement with Non-State Actors

Posted on by Claire Cassedy

On Friday May 8, 2015, the US Department of Health and Human Services held a listening session to solicit input on the agenda items for the upcoming 68th World Health Assembly. KEI delivered five interventions covering a range of critical WHA topics. The full provisional agenda of the 68th WHA can be accessed here: http://apps.who.int/gb/ebwha/pdf_files/WHA68/A68_1-en.pdf
jimmy-claire_1024x.png

Continue Reading →

Seminars on Drug Pricing: Part 1, Paul Grootendorst

Posted on by Claire Cassedy

Today, KEI hosted the first talk in a series of seminars on drug pricing. The seminar, conducted via video conference, focused on the Canadian approach to drug pricing. Each seminar in the series is intended to contribute to the discussion on drug pricing and how we can improve affordability and access to medicines. Paul Grootendorst began with a presentation (the slides are available here), before opening up the discussion to questions from those participating in the video conference.

Continue Reading →